[3H-Benzothiazol-(2Z)-ylidene]-{2-[2-(3-chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-acetonitrile

ID: ALA425722

Max Phase: Preclinical

Molecular Formula: C21H16ClN5S

Molecular Weight: 405.91

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccc(Cl)c2)n1

Standard InChI:  InChI=1S/C21H16ClN5S/c22-15-5-3-4-14(12-15)8-10-24-21-25-11-9-17(27-21)16(13-23)20-26-18-6-1-2-7-19(18)28-20/h1-7,9,11-12,26H,8,10H2,(H,24,25,27)/b20-16+

Standard InChI Key:  IRJZMMMMXQUTQV-CAPFRKAQSA-N

Molfile:  

     RDKit          2D

 28 31  0  0  0  0  0  0  0  0999 V2000
    1.4875   -2.4292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3125   -2.4292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9917   -1.7625    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9917   -3.1042    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    2.3125   -1.0125    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.7250   -1.7167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7167   -0.2917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7250   -3.1500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2042   -2.0167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2042   -2.8500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1375   -3.8625    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.5500   -0.2917    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.3042    0.4208    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.5500   -1.7167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9625   -1.0042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1750    1.8333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0000    1.8333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4125    2.5458    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    0.2375    1.1250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4792    0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5083   -1.6042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5083   -3.2625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9875    0.4000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0625    1.1250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4083    1.1208    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1708    0.4083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2208   -2.0250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2208   -2.8500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  1  1  0
  4  1  1  0
  5  6  1  0
  6  2  1  0
  7  5  2  0
  8  2  1  0
  9  3  1  0
 10  4  1  0
 11  8  3  0
 12 15  2  0
 13  7  1  0
 14  6  2  0
 15 14  1  0
 16 19  2  0
 17 16  1  0
 18 17  1  0
 19 24  1  0
 20 13  1  0
 21  9  2  0
 22 10  2  0
 23 26  2  0
 24 20  1  0
 25 23  1  0
 26 19  1  0
 27 21  1  0
 28 22  1  0
  9 10  1  0
 27 28  2  0
  7 12  1  0
 17 25  2  0
M  END

Alternative Forms

  1. Parent:

    ALA425722

    ---

Associated Targets(non-human)

Mapk10 c-Jun N-terminal kinase 3 (129 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 405.91Molecular Weight (Monoisotopic): 405.0815AlogP: 5.19#Rotatable Bonds: 5
Polar Surface Area: 73.63Molecular Species: NEUTRALHBA: 6HBD: 2
#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 11.25CX Basic pKa: 2.59CX LogP: 5.08CX LogD: 5.08
Aromatic Rings: 3Heavy Atoms: 28QED Weighted: 0.57Np Likeness Score: -1.46

References

1. Gaillard P, Jeanclaude-Etter I, Ardissone V, Arkinstall S, Cambet Y, Camps M, Chabert C, Church D, Cirillo R, Gretener D, Halazy S, Nichols A, Szyndralewiez C, Vitte PA, Gotteland JP..  (2005)  Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.,  48  (14): [PMID:15999997] [10.1021/jm0310986]

Source